Zydus Life rises on USFDA nod for dyskinesia treatment drug
Zydus Lifesciences gained 1.49% to Rs 1130.50 after it received final approval from the United States Food and Drug Administration (USFDA) to market Amantadine extended-release capsules, 68.5 mg, and tentative approval for 137 mg.